Company: STAA
Filing Date: 2025-12-10
Form Type: DEFA14A
Source: 0001193125-25-314435
Chunk: 1

Company: STAAR SURGICAL CO
Filing Date: 2025-12-10
Form: DEFA14A
Chunk 1
---
 meanings ascribed to such terms in the proxy statement. Except as
described in this Supplement, the information provided in the proxy statement relating to the Merger Agreement and the transactions contemplated thereby continue to apply. This Supplement and the documents referred to in this Supplement should be
read in conjunction with the proxy statement, the annexes and exhibits to the proxy statement and the documents referred to in the proxy statement, each of which should be read in its entirety. All page references herein are to pages in the proxy
statement, except where otherwise specified. To the extent that information in this Supplement differs from, updates or conflicts with information contained in the proxy statement, the information in this Supplement supersedes the information in the
proxy statement. For clarity, new text within restated paragraphs from the proxy statement is highlighted with bold, underlined text, while deleted text is bold and stricken-through.

As previously disclosed, on August 4, 2025, STAAR entered into an Agreement and Plan of Merger (as it may be amended from time to time,
including by Amendment No. 1 on November 7, 2025 (the “First Amendment”) and Amendment No. 2 on December 9, 2025 (the “Second Amendment” and together with the First Amendment, the
“Amendments”), the “Merger Agreement”) with Alcon Research, LLC, a Delaware limited liability company (“Alcon”), and Rascasse Merger Sub, Inc., a Delaware corporation and a wholly owned direct subsidiary of Alcon
(“Merger Sub”), pursuant to which, subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into STAAR (the “Merger”), with STAAR surviving the Merger as a wholly owned
subsidiary of Alcon.

As disclosed by STAAR on a Current Report on Form 8-K filed on December 9, 2025, on December 9, 2025,
Alcon, Merger Sub and STAAR entered into the Second Amendment. The Second Amendment provides, among other things, for an increase in the consideration payable to holders of shares of common stock of STAAR (“STAAR common stock”). Pursuant
to the Second Amendment, each issued and outstanding share of STAAR common stock as of the date and time the Merger is effective (other than certain excluded shares as described in the Merger Agreement) shall be converted into the right to receive
$30.75 per share in